The deal sees Endocyte acquire an exclusive worldwide licence for ABX’s phase 3-ready prostate cancer candidate 177Lu ... in 40% to 60% of patients, and a RECIST response rate in soft tissue ...

It’s tough for a man to know what to do following a diagnosis of prostate cancer.The treatment is often worse than the ...

The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancerscreeningis highly accurate. The exciting new results, published in The Journal ...

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate.

A recent study finds that genetically predicted rheumatoid arthritis is causally associated with prostate cancer.

Following a change in screening guidelines, the incidence went up across the state, even more than it has nationally.

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

A new study from UCSF reveals an “alarming” rise in advanced prostate cancer rates across California. The findings, published ...

You can’t pretend the pink pachyderm isn’t staring you in the face on Saturday. But if you must draw attention to it, at least soften the hard edges of your truth with graceful diplomacy. A ...

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...